Merck & Co. is paying $10.8 billion to buy Prometheus Biosciences for its late-phase bowel disease drug candidate. Months after midphase data sent Prometheus’ stock spiraling upward, Merck has agreed ...

Just days before a planned celebration of its new Rahway headquarters, Merck announced another milestone: It officially closed on its previously announced $10.8 billion acquisition of San Diego-based ...

Merck announced Sunday morning that it is purchasing Prometheus Biosciences for nearly $11 billion. As part of the definitive agreement, Merck will acquire Prometheus’ lead candidate, PRA023, an anti ...

Merck & Co. has agreed to acquire Prometheus Biosciences for about $10.8 billion, the companies said Sunday, in a deal intended to bolster the buyer’s immunology drug pipeline as it faces loss of ...

The deal for Prometheus is expected to close in the third quarter Terry Lane is a writer for Investopedia with 25 years of experience in journalism and communications. He covers personal finance, ...

Merck & Co. announced that it will acquire the immunology company, Prometheus Biosciences, which specializes in inflammatory bowel disease (IBD) treatments. Under the terms of the deal, Merck will ...

Merck & Co., Inc. has reached a near $11 billion deal to acquire Prometheus Biosciences, Inc. The deal adds to the pipeline, badly needed as Keytruda reliance is high and growing. The transaction ...

Pharma goliath, Merck MRK and Prometheus Biosciences, Inc RXDX, together announced entering a definitive agreement where the former is set to acquire the latter, through a subsidiary for $200 per ...

Merck MRK0.58%increase; green up pointing triangle & Co. said it agreed to acquire Prometheus Biosciences Inc. for $10.8 billion, a push into the lucrative market for immune-disease treatments. Merck ...